Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men and women between 30 and 85 years old
- People with pre-diabetes, meaning their blood sugar levels are slightly above normal but not yet in the diabetes range (confirm with trial site for specific test values)
- People with normal blood sugar levels who could serve as a comparison group (confirm with trial site for specific test values)
- People diagnosed with Type 2 Diabetes who have moderately elevated blood sugar levels, but not severely uncontrolled (confirm with trial site for specific test values)
Who may not be able to join:
- People who have signs or symptoms of nerve damage (such as numbness, tingling, or pain in the hands or feet)
- People taking medications linked to more advanced Type 2 Diabetes, including insulin
- People with very poorly controlled blood sugar levels
- People who have swelling caused by fluid buildup in their limbs
- People with severe obesity (a BMI greater than 45)
- People with an underactive thyroid that is not being treated
- People who currently smoke
- People with high blood pressure
- People with heart or joint/muscle conditions that would prevent them from safely doing exercise tests
- People taking hormone replacement therapy or medications that affect blood vessel function
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (734) 647-9819
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Fatigability - Reduction in Power; Strength - 1 Repetition Maximum; Strength - Maximal Voluntary Contraction (MVC); Leg Blood Flow; Skeletal Muscle Oxygenation; Vasodilation in Skeletal Muscle Arterioles; Muscle Metabolism - Phosphorus Nuclear Magnetic Resonance Spectroscopy (31P-MRS)); Capillary density
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.